ARS Pharmaceuticals (SPRY) Total Current Liabilities (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Total Current Liabilities data on file, last reported at $49.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 79.61% year-over-year to $49.6 million; the trailing twelve-month figure through Mar 2026 stood at $49.6 million (up 79.61% YoY), and the FY2025 full-year result was $39.1 million, up 67.0% from the prior year.
• Total Current Liabilities improved to $49.6 million in Q1 2026, from $39.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $50.9 million in Q3 2025 to a low of $2.4 million in Q4 2023.
• A 5-year average of $19.5 million and a median of $11.2 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities tumbled 74.0% in 2022 and surged 880.34% in 2024, its largest moves.
• Tracing SPRY's Total Current Liabilities over 5 years: stood at $5.4 million in 2022, then sank by 56.08% to $2.4 million in 2023, then surged by 880.34% to $23.4 million in 2024, then soared by 67.0% to $39.1 million in 2025, then gained by 26.74% to $49.6 million in 2026.
• Business Quant data shows SPRY's Total Current Liabilities at $49.6 million in Q1 2026, $39.1 million in Q4 2025, and $50.9 million in Q3 2025.